Novel 4-drug combination proves safe for lung cancer treatment

November 13, 2008

Study first to combine 2 chemotherapies and 2 targeted therapies

CHICAGO - The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.

Presented today on the press program of the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago, the study is the first to investigate in lung cancer a four-drug regimen of two standard chemotherapies and targeted therapies.

The Southwest Oncology Group (SWOG) Phase II study was led by Edward S. Kim, M.D., assistant professor in M. D. Anderson's Department of Thoracic Head and Neck Medical Oncology. Until now, the SWOG standard regimen for lung cancer has been carboplatin, paclitaxel and Erbitux, explained Kim; with the addition of Avastin, this study looked to increase efficacy without compromising safety.

"We could not conduct a study with four chemotherapeutic agents in patients due to toxicity concerns," said Kim, the study's principal investigator. "The rationale behind the study was the finding that Avastin enhances the efficacy of existing therapy, thereby possibly improving the carboplatin-paclitaxel-Erbitux regimen."

Data in lung cancer has also suggested there's a "synergistic effect" of pairing the epidermal growth factor (EGFR) inhibitor compounds with the vascular endothelial growth factor (VEGF) inhibitor, explained Kim.

Interestingly, explained Kim, the SWOG's study came at a crossroads for lung cancer - soon after a study was presented showing the benefits of adding Avastin to standard chemotherapy, and prior to a study showing a modest survival benefit when Erbitux is combined with chemotherapy.

Between August 2006 and September 2007, the large Phase II study enrolled 110 Stage IIIB or IV non-small cell lung cancer patients, 99 of whom were able to be evaluated. Patients received six cycles of the four-drug regimen, and as maintenance, continued receiving both Avastin and Erbitux. It's unique for a trial to feature a two-drug maintenance biologic therapy combination, explained Kim.

The study met its primary endpoint, safety, defined by frequency of pulmonary hemorrhage, or bleeding, a concern related to Avastin. There were four treatment-related deaths and two due to bleeding, which is consistent with prior Avastin studies, explained Kim. Adverse events such as low blood counts and neuropathy were reported in 40 patients, also consistent with standard chemotherapy.

Secondary endpoints included response rate, progression-free survival and overall survival. Of patients enrolled, 53 percent had shrinkage of their tumors and 24 percent had stable disease. The median progression-free survival rate was seven months and overall survival was 14 months. In contrast, previous SWOG studies showed an average progression-free survival rate of five-and-a-half months and overall survival of 12 months.

"These findings were certainly compelling, and are the best results ever for a SWOG-based study for advanced lung cancer. While early, this four-drug combination seems to show promising, yet modest improvement in efficacy without compromising patients' safety," said Kim. "Our next priority will be to analyze the tissue from this to study to help find appropriate biomarkers for the disease to best understand who might benefit from this drug regimen."

A biomarker analysis of this study is ongoing and a randomized Phase III study is planned, with the trial scheduled to open in 2009.

University of Texas M. D. Anderson Cancer Center

---

---

	Johns Hopkins Patients' Guide to Lung Cancer by Justin F. Klamerus (Author), Julie R. Brahmer (Author), David S Ettinger (Author) Johns Hopkins Patients' Guide to Lung Cancer is a concise, easy-to-follow how to guide that puts you on the path to wellness by explaining lung cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.
	Lung Cancer: A Guide to Diagnosis and Treatment by Walter J. Scott MD (Author) What is my prognosis? What are my treatment options? Which therapies would be the most effective for my stage of lung cancer? These and other frequently asked questions are addressed in this crucial reference designed to help patients educate themselves and obtain the best possible treatments. The completely revised second edition has been updated to include a discussion of the movement towards customized chemotherapy; treatment options for early-stage lung cancer including minimally invasive surgery; and the most promising treatments, among them multimodality therapy—a combination of surgery, chemotherapy, and radiation. Dr. Scott also surveys tests for early detection of lung cancer, talks about the importance of cancer staging, examines alternative treatments, and offers advice on...
	Lung Cancer: Myths, Facts, Choices--and Hope by Claudia I. Henschke (Author), Peggy McCarthy (Author), Sarah Wernick (Contributor) An authoritative book with new lifesaving strategies for those at risk and those already diagnosed.Lung cancer kills more women than breast cancer, more men than prostate cancer. This authoritative book presents new lifesaving strategies for those already diagnosed and those at risk (including ex-smokers). Lung cancer is deadly because it's usually found late. Dr. Claudia Henschke's groundbreaking research on early diagnosis, published in Lancet, made headlines worldwide. Now, for the first time, she offers specific recommendations based on her latest findings: who needs to be checked and how to get tested. People with lung cancer often are told, "Nothing can be done." Not so! Dr. Henschke and coauthor Peggy McCarthy, a leading patient advocate, provide...
	Be A Survivor: Lung Cancer Treatment Guide by Vladimir Lange MD (Author) This much needed lung cancer resource is developed in consultation with a large national team of experts featuring: * Candid testimonials by survivors * Straightforward, easy-to-understand language * Objective and up-to-date information * Beautiful color photos and graphics * An empowering message of HOPE. The book addresses each step in the diagnosis, staging, treatment and recovery process, and includes a chapter on end-of-life issues, and a section specifically for the patient's partner or caregiver.
	Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC) (Pass, Lung Cancer) by Harvey I. Pass (Editor), David P. Carbone (Editor), David H. Johnson (Editor), John D. Minna (Editor), Giorgio V. Scagliotti (Editor), Andrew T. Turrisi (Editor) Thoroughly revised and updated, this Fourth Edition is the most comprehensive, current reference on lung cancer, with contributions from the world's foremost surgeons, radiation oncologists, medical oncologists, pulmonologists, and basic scientists. Coverage includes complete information on combined modality treatments for small cell and non-small cell lung cancer and on complications of treatment and management of metastases. Emphasis is also given to early detection, screening, prevention, and new imaging techniques. This edition has expanded thoracic oncology chapters including thymus, mesothelioma, and mediastinal tumors, more detailed discussion of targeted agents, and state-of-the-art information on newer techniques in radiotherapy. Other highlights include more international...
	100 Questions & Answers About Lung Cancer, Second Edition by Karen Parles (Author), Joan H. Schiller (Author), Amy Cipau (Author) Empower yourself! No one with lung cancer needs to be alone in their fight against this disease. 100 Questions & Answers About Lung Cancer, Second Edition enables patients and their families to seek our the best treatment possible for early detection of lung cancer. Providing both the doctor s and patient s point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through 100 Questions & Answers About Lung Cancer, Second Edition, expert authors use their experiences with patients to provide support and hope to the tens of thousands of people coping with this disease.
	How to Survive Lung Cancer - A Practical 12-Step Plan by Michael Lloyd (Author) Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter summaries.
	Lung Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages Of Lung Cancer - Revised Edition - Illustrated by S. Smith by Department of Health and Human Services (Author), National Institutes of Health (Author), National Cancer Institute (Author), S. Smith (Editor), S. Smith (Editor)
	Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management (Current Multidisciplinary Oncology) by Kemp Kernstine MD PhD (Editor), Karen Reckamp MD MS (Editor), Charles Thomas Jr. MD (Editor) Over the course of the last decade, the treatment of lung cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of lung cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment. Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management, written by a multidisciplinary team of authors representing a range of disciplines, is a valuable...
	Voices of Lung Cancer: The Healing Companion: Stories for Courage, Comfort and Strength (Voices Of series) by The Healing Project (Editor), S. Epatha Merkerson (Editor) Provided by the patients, their friends, families, and caregivers of those diagnaosed with lung cancer, these very personal stories offer inspired insight into the ways families and professionals care for both themselves and the patient, gain a deeper understanding of the relationships, and learn to come to terms with the end of life. Included are essays by medical experts about the science of lung cancer, current treatments, choosing the right doctors, and what the future holds for the next generation of patients.